Medincell Aligns Debt Maturity with Revenue Growth Expectations

Medincell has announced an extension of its debt maturity to mid-2031, aligning with its anticipated revenue growth largely driven by UZEDY® and Olanzapine LAI. The latter is under regulatory review in the U.S. and Europe. This move involves securing €28 million in non-dilutive new bank loans and early repayment of half of its €40 million European Investment Bank (EIB) credit facility.

The €28 million in loans, sourced from leading European commercial banks, aims to enhance Medincell's financial stability without introducing covenants or equity-linked instruments. Concurrently, Medincell plans to repay €20 million of principal plus interest from its existing EIB credit facility by the end of July 2026, reducing financial costs by approximately €1 million.

According to CEO Christophe Douat, this strategic financial realignment supports Medincell's 'Shift to Growth' strategy and upcoming product launches, enhancing long-term value creation.